Navigation Links
New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)

NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective  as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH).

BPH, also known as an enlarged prostate, is the most common benign proliferative disorder in men, affecting more than 50 percent of men over the age of 70. Symptoms include urinary hesitancy, weak urine stream, nocturia, incontinence, and recurrent urinary tract infections.  

The study, sponsored by Euromed, makers of SPET-085, evaluated the in-vitro potency of SPET-085, an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system. It revealed that SPET-085 can effectively inhibit the enzyme linked to BPH, at a lower dose as compared to hexane  extracts of saw palmetto, currently regarded as the most clinically effective saw palmetto, but unavailable in the United States.  Importantly, the study revealed that SPET-085 has bioactivity similar to finasteride, the most commonly prescribed prescription medicine for the treatment of BPH.  Common finasteride side effects may include decreased sex drive, impotence, or decreased ejaculate amount.

"I look forward to seeing if these interesting results in the laboratory translate into better patient outcomes in the National Institutes of Health-funded CAMUS study, an ongoing 18 month clinical trial comparing this saw palmetto supplement against a placebo for urinary symptoms attributed to benign prostatic enlargement," said Michael J. Barry, M.D., Professor of Medicine, Harvard Medical School.

While finasteride is currently the most common treatment for BPH, SPEs provide a more natural phytotherapeutic alternative to manage symptoms of the condition. There are many types of SPEs available today, based on a variety of extraction processes.  This study demonstrates that the approach to extraction may impact levels of BPH-related bioactivity among the various extracts of saw palmetto.

"The results of this study verify the high activity of our novel saw palmetto extract, SPET-085, to help maintain healthy prostate function," said Joe Veilleux, General Manager, Euromed USA. "Euromed is committed to ongoing clinical research to provide scientific evidence which will differentiate SPET-085 from other saw palmetto extracts."

About the Study

The nicotinamide adenine dinculeotide phosphate (NADPH)-dependent membrane protein 5alpha-reductase irreversibly catalyses the conversion of testosterone to the most potent androgen, 5alpha-dihydrotestosterone (DHT).  In humans, two 5alpha-reductase isoenzymes are expressed: type I and type II. Type II is found primarily in prostate tissue. Saw palmetto extract (SPE) has been widely used for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). The mechanisms of the pharmacological effects of SPE include the inhibition 5alpha-reductase, among other actions. Clinical studies of SPE have been equivocal, with some showing significant results and others not. These inconsistent results may be due, in part, to varying bioactivities of the SPE used in the studies.

The aim of the present study was to determine the in vitro potency of a novel saw palmetto ethanol extract (SPET-085) an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system. On the basis of the enzymatic conversion of the substrate androstenedione to the 5alpha-reductase product 5alpha- androstenedione, an inhibitory potency was measured and compared to those of finasteride, an approved 5alpha-reductase inhibitor.

SPET-085 concentration-dependently inhibited 5alpha-reductase type II in vitro. The approved 5alpha-reductase inhibitor, finasteride, tested as positive control, led to 61% inhibition of 5alpha-reductase type II.

About SPET-085

Euromed saw palmetto extract, known as SPET-085, is a standardized herbal extract of Sabal serrulata Roem et Schult fruits, a small species of palms native to the USA.  Saw palmetto extract is commonly used to help maintain prostate health and address symptoms associated with BPH – often referred to as enlarged prostate. Symptoms of BPH include: urinary hesitancy, weak urine stream, nocturia, incontinence, and recurrent urinary tract infections. The saw palmetto extract from Euromed gives most patients some relief of symptoms within the first 30 days of use.

About Euromed

Euromed is one of the world's most well-known and well-respected manufacturers of standardized botanical (herbal) extracts.  Euromed extracts have been utilized in numerous human clinical studies including those evaluating saw palmetto, milk thistle, St. John's Wort and others. Euromed extracts are used for supplement, pharmaceutical, nutraceutical, and cosmetic purposes. Euromed was founded in 1971 as a part of the multi-national phytopharmaceutical company MADAUS (Cologne, Germany) and since 2007 part of the Rottapharm/Madaus Group headquartered in Monza Italy. For more information about Euromed, please call toll free 877-696-3960 or visit  

SOURCE Euromed
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
2. Drug Study Shows Improvement in Major Orthopedic Surgery Care
3. Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies
4. Nile Therapeutics Completes Dosing of Phase II Study
5. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
8. Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients
9. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
10. PARI Pharmas Altera Delivers Gileads Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
11. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Post Your Comments:
(Date:12/1/2015)... Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, announced ... data collection of vital signs. Photo - ... ... ... ...
(Date:12/1/2015)... , Dec. 1, 2015 Ampio Pharmaceuticals, ... York Stock Exchange has established January 5, 2016 as the ... stockholders of the shares of Common Stock of Aytu ... share of Aytu common stock for every five (5) ... record date, December 1, 2015. The distribution date will be ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... International Breast Cancer Study Group (IBCSG, Bern ... ) to be part of a state of the ... cancer drug.  --> --> ... cancer being treated with anti-hormonal therapy in combination with palbociclib, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Lutronic, a ... of Clarity, the latest addition to the devices for sale in the United States. ... nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):